



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ion of information unless it contains a valid OMB control number.

(use as many sheets as necessary)

Application Number	10/535,189
Filing Date	September 21, 2006
First Named Inventor	Alexei SHIR et al
Art Unit	1635
Examiner Name	GIBBS, TERRA C
Attorney Docket Number	29770

Sheet	1	of	4
-------	---	----	---

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ² Number ⁴ Kind Code ³ (if known)				
/TCG/	1	PCT WO 01/43777	06-21-2001	Aigner et al. ONLY ABSTRACT CONSIDERED		
/TCG/	2	PCT WO 94/23050	10-13-1994	Chiou et al.		
Examiner Signature	/Terra Cotta Gibbs/			Date Considered	12/06/2007	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/535,189
				Filing Date	September 21, 2006
				First Named Inventor	Alexei SHIR et al
				Group Art Unit	1635
				Examiner Name	GIBBS, TERRA C
Sheet	2	of	4	Attorney Docket Number	29770
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/TCG/	3	Ogris et al. "DNA/Polyethylenimine Transfection Particles: Influence of Ligands, Polymer Size, and PEGylation on Internalization and Gene Expression", AAPS PharmSci 3(3): Article 21: 1-11, 2001.			
	4	Sosnowski et al. "Targeting DNA to Cells with Basic Fibroblast Growth Factor (FGF2)", Journal of Biological Chemistry 271(52): 33647-33653, 1996.			
	5	Xu et al. "The Contribution of Poly-L-Lysine, Epidermal Growth Factor and Streptavidin to EGF/PLL/DNA Polyplex Formation", Gene Therapy 5: 1235-1243, 1998.			
	6	Shir et al. "Efficient Killing of Glioblastoma and Other Cancers by Cancer Specific Transfection of dsRNA"			
	7	Shir et al. "Inhibition of Glioma Growth by Tumor-Specific Activation of Double-Stranded RNA-Dependent Protein Kinase PKR", Nature Biotechnology 20(9): 895-900, 2002. Abstract.			
	8	Merdan et al. "Prospects for Cationic Polymers in Gene and Oligonucleotide Therapy Against Cancer", Advanced Drug Delivery Reviews, 54(5): 715-758, 2002.			
	9	Blessing et al. "Different Strategies for Formation of PEGylated EGF-Conjugated PEI/DNA Complexes for Targeted Gene Delivery", Bioconjugate Chemistry, 12(4): 529-537, 2001. Abstract.			
	10	Bettinger et al. "Peptide-Mediated RNA Delivery: A Novel Approach for Enhanced Transfection of Primary and Post-Mitotic Cells", Nucleic Acids Research, 29(18): 3882-3891, 2001. Abstract.			
	11	Liu et al. "Double-Stranded Ribonucleic Acid (RNA) Induces β -Cell Fas Messenger RNA Expression and Increases Cytokine-Induced β -Cell Apoptosis", Endocrinology, 142(6): 2593-2599, 2001. Abstract.			
	12	Shir et al. "EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice", PLoS Medicine, 3(1/e6): 0125-0135, 2006.			
	13	Bansal et al. "Gene Therapy for Brain Tumors", Current Oncology Reports, 2: 463-472, 2000.			
	14	Bukrinsky et al. "A Nuclear Localization Signal Within HIV-1 Matrix Protein That Governs Infection of Non-Diving Cells", Nature, 365: 666-669, 1993.			
	15	Eriksdotter Joenhagen "Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients With Alzheimer's Disease", Dementia and Geriatric Cognitive Disorders, 9: 246-257, 1998.			
/TCG/	16	Farrell et al. "Interferon Action: Two Distinct Pathways for Inhibition of Protein Synthesis by Double-Stranded RNA", Proc. Natl. Acad. Sci. USA, 75(12): 5893-5897, 1978.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/535,189	
				Filing Date	September 21, 2006	
				First Named Inventor	Alexei SHIR et al	
				Group Art Unit	1635	
				Examiner Name	GIBBS, TERRA C	
Sheet	3	of	4	Attorney Docket Number		29770
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/TCG/	17	Gallay et al. "HIV Nuclear Import Is Governed by the Phosphotyrosine-Mediated Binding of Matrix to the Core Domain of Integrase", Cell, 83: 569-576, 1995.				
	18	George "Platelet-Derived Growth Factor Receptors: A Therapeutic Target in Solid Tumors", Seminars in Oncology, 28(5/Suppl.17): 27-33, 2001.				
	19	Giles "The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients With Hematologic Malignancies", The Oncologist, 6(Suppl.5): 32-39, 2001.				
	20	Jordanov et al. "Activation of P38 Mitogen-Activated Protein Kinase and C-Jun NH2-Terminal Kinase by Double-Stranded RNA and Encephalomyocarditis Virus: Involvement of RNase L, Protein Kinase R, and Alternative Pathways", Molecular and Cellular Biology, 20(2): 617-627, 2000.				
	21	Jagus et al. "PKR, Apoptosis and Cancer", The International Journal of Biochemistry & Cell Biology, 31: 123-138, 1999.				
	22	Kim et al. "Epidermal Growth Factor Receptor Biology", Current Opinion in Oncology, 13(6): 506-513, 2001.				
	23	Lappi "Tumor Targeting Through Fibroblast Growth Factor Receptors", Seminars in Cancer Biology, 6: 279-288, 1995.				
	24	Nagane et al. "Drug Resistance of Human Glioblastoma Cells Conferred by A Tumor-Specific Mutant Epidermal Growth Factor Receptor Through Modulation of Bcl-XL and Caspase-3-Like Proteases", Proc. Natl. acad. Sci. USA, 95: 5724-5729, 1998.				
	25	Nakamura et al. "Effect of Interferon Inducer (Poly ICLC) in the Treatment of Malignant Brain Tumor", No To Shinkei, 34(3): 267-273, 1982. Abstract. Article in Japanese. Abstract in English.				ONLY ABSTRACT CONSIDERED
	26	Nishikawa et al. "A Mutant Epidermal Growth Factor Receptor Common in Human Glioma Confers Enhanced Tumorigenicity", Proc. Natl. Acad. Sci. USA, 91: 7727-7731, 1994.				
	27	Player et al. "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation", Pharmacological Therapy, 78(2): 55-113, 1998.				
	28	Rosen "Angiogenesis Inhibition in Solid Tumors", Cancer Journal, 7(Suppl.3): 120-128, 2001.				
↓ /TCG/	29	Salazar et al. "Long-Term Treatment of malignant Gliomas With Intramuscularly Administered Polyinosinic-Polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose: An Open Pilot Study", Congress of Neurological Surgeons, 38(6): 1096-1104, 1996.				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Signature	/Terra Cotta Gibbs/	Considered	12/06/2007
-----------	---------------------	------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ☐ Please check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.